glp-1 receptor agonist kidney outcomes semaglutide flow trial 2024 results Updated evidence on cardiovascular and renal effects of agonists and combination therapy with SGLT2 inhibitors and finerenone: a narrative review and perspectives | Cardiovascular Diabetology Semaglutides Are Poised to Remake

Effectiveness: The potential weight loss results for Zepbound mirror those reported above for Mounjaro, since they share the same active ingredients and dose strengths

Rawshani A, Rawshani A, Gudbjrnsdottir S (2017) Mortality and cardiovascular disease in type 1 and type 2 diabetes

This policy ensures patients can explore treatment options with confidence, knowing they will not incur unnecessary costs if GLP-1 therapy is not suitable

Atherosclerotic CVD manifest as heart attacks and strokes, is responsible for up to 85 per cent of cardiovascular deaths [1]

79,80 In the treatment of T2DM, liraglutide helps lower blood sugar levels by increasing insulin production and reducing glucose production by the liver

The beneficial effects of GLP-1 RAs on HRQoL and other outcomes in HFpEF are likely due to pleiotropic impacts, related or not to weight reduction, such as decongestion (mainly due to the reduction of increased plasma volume associated with obesity and epicardial constrain), reverse cardiac remodelling (mainly due to the decrease in epicardial fat and regression of left atrial and LV myopathy, lowering intracardiac pressure) and anti-inflammatory actions, among others